峡谷伙伴安排并牵头融资，以支持阿文特国际对NZCR集团的投资-动脉网

Canyon Partners Arranges and Anchors Financing to Support Advent International's Investment in NZCR Group

CISION 等信源发布 2026-09-29 20:30



可切换为仅中文







DALLAS

达拉斯

，

Sept. 29, 2026

2026年9月29日

/PRNewswire/ -- Canyon Partners, LLC ('Canyon'), a $30 billion global alternative investment manager, today announced that it has served as arranger and anchor lender for a NZ$300 million financing to support Advent International's ('Advent') acquisition of NZCR Group ('NZCR'), a leading clinical trials and medical research organization in New Zealand and Australia..

/美通社/ -- 全球另类资产管理公司、管理规模达300亿美元的Canyon Partners, LLC（“Canyon”）今日宣布，其担任了一笔3亿新西兰元融资的牵头安排行和锚定贷款人，以支持Advent International（“Advent”）收购NZCR Group（“NZCR”）。NZCR是新西兰和澳大利亚领先的临床试验和医学研究机构。

NZCR Group is a leading physician-led clinical research organisation with more than 35 years of research experience and a strong track record in complex early and later-phase studies. Headquartered in Auckland, the company has operations across Australia and New Zealand (ANZ).

NZCR集团是一家领先的由医生主导的临床研究组织，拥有超过35年的研究经验，在复杂的早期和后期阶段研究方面有着良好的业绩记录。公司总部位于奥克兰，业务遍及澳大利亚和新西兰（ANZ）。

The financing enables Advent to support the company's next stage of growth and work alongside the NZCR management team as they look to further enhance the group's capabilities across the clinical trial spectrum, with a particular focus on strengthening sponsor and CRO relationships and international reach as part of the Advent portfolio..

此次融资使安宏资本能够支持公司下一阶段的成长，并与新西兰临床研究中心（NZCR）管理团队携手合作，进一步提升集团在整个临床试验领域的综合能力，特别侧重于加强作为安宏资本投资组合一部分的申办方和合同研究组织（CRO）合作关系以及国际拓展。

'We are excited to support NZCR's continued development and to work again with Advent, whose deep sector expertise and strong track record of partnering with management teams make them an ideal fit for the business,' said Davide Amico, Partner and Co-Head of Private Credit at Canyon. 'It's our pleasure to leverage our capabilities as a global investment firm to support Advent on deals originated from their new Australian office and be a reliable financing partner in the ANZ market as we long have in the United States, Europe and beyond.'.

Canyon 的合伙人兼私募信贷联席主管 Davide Amico 表示：“我们很高兴支持 NZCR 的持续发展，并再次与 Advent 合作。Advent 拥有深厚的行业专业知识以及与企业管理层合作的卓越记录，使其成为该业务的理想合作伙伴。”他补充道：“我们很荣幸能够发挥作为全球投资公司的能力，支持 Advent 由其新设立的澳大利亚办公室发起的交易，并在澳新市场充当可靠的融资合作伙伴，正如我们在美国、欧洲及其他地区长期以来所做的那样。”

Canyon's investment is underpinned by the sustained growth of the ANZ clinical research market and NZCR's strong positioning within the sector as a reliable and trusted partner to biotech and pharma sponsors globally.

Canyon 的投资基于澳大利亚和新西兰（ANZ）临床研究市场的持续增长，以及新西兰临床研究中心（NZCR）在该领域作为全球生物技术和制药申办方可靠且值得信赖的合作伙伴的强劲地位。

'NZCR has built a strong platform with meaningful growth momentum, and we see significant opportunity as the ANZ market continues to attract an increasing share of global clinical trial activity,' said Maximilian Lichtenheld, Managing Director at Canyon. 'We are pleased to support Advent as they bring their expertise to this next stage of growth, working alongside existing management to help the business capitalize on these opportunities.'.

“NZCR已经构建了一个强大的平台，拥有显著的增长动力。随着澳新市场继续吸引全球临床试验活动中日益增长的份额，我们看到了巨大的机遇。”Canyon的执行董事Maximilian Lichtenheld表示。“我们很高兴在Advent将其专业知识带入这一新的增长阶段时提供支持，并与现有管理层合作，帮助企业抓住这些机遇。”

'Advent has been following NZCR Group's success and growth for over 18 months, and we continue to be impressed by the quality of the platform, its clinical leadership, and the trust it has built with biopharma and biotech clients,' remarked Beau Dixon, Managing Director and Head of Australia and New Zealand at Advent.

Advent董事总经理兼澳大利亚和新西兰负责人Beau Dixon表示：“在过去18个多月里，Advent一直密切关注NZCR集团的成功与成长。该平台的卓越品质、其临床领导能力，以及它在生物制药和生物技术客户中建立的信任，持续令我们印象深刻。”

'We look forward to partnering with management and existing shareholders to unlock NZCR Group's full potential and introduce the business into Advent's global network. We see exceptional opportunities to build on NZCR Group's strengths while preserving the clinical focus that underpins its success.'.

“我们期待与管理层及现有股东合作，充分释放NZCR集团的全部潜力，并将其业务引入Advent的全球网络。我们认为，在保持支撑其成功的临床专注度的同时，基于NZCR集团的优势进行拓展，存在非凡的机遇。”

About Canyon Partners, LLC

关于 Canyon Partners, LLC

Founded in 1990, Canyon employs a deep value, credit intensive approach across public and private corporate credit, asset-backed credit, and real estate. The firm seeks to capture excess returns available to those investors with specialized expertise, rigorous research capabilities, and the ability to underwrite complexity.

Canyon 成立于 1990 年，在公开和私募公司信贷、资产支持信贷以及房地产领域采用深度价值且高度侧重信贷的投资方法。该公司旨在为那些拥有专业专长、严谨研究能力以及能够承销复杂交易的投资者捕捉超额回报。

Canyon invests on behalf of a broad range of institutions globally. For more information visit .

Canyon 代表全球各类广泛的机构进行投资。欲了解更多信息，请访问。

www.canyonpartners.com

。

About Advent

关于降临节

Advent is a leading global private equity investor committed to working in partnership with management teams, entrepreneurs, and founders to help transform businesses. With 17 offices across five continents, we oversee more than USD $94 billion in assets under management* and have made 451 investments across 45 countries..

Advent 是一家领先的全球私募股权投资机构，致力于与管理团队、企业家和创始人建立合作伙伴关系，助力企业实现转型。我们在五大洲设有 17 家办公室，管理资产规模超过 940 亿美元*，并在 45 个国家完成了 451 项投资。

Since our founding in 1984, we have developed specialist market expertise across our five core sectors: business & financial services, consumer, healthcare, industrial, and technology. This approach is bolstered by our deep sub-sector knowledge, which informs every aspect of our investment strategy, from sourcing opportunities to working in partnership with management to execute value creation plans.

自1984年成立以来，我们在五大核心领域——商业与金融服务、消费、医疗健康、工业和科技——积累了专业的市场专长。这一方法得益于我们对细分领域的深刻理解，这种理解贯穿于我们投资策略的各个环节，从发掘投资机会到与管理层携手合作，共同执行价值创造计划。

We bring hands-on operational expertise to enhance and accelerate businesses..

我们提供实战运营专长，以增强并加速企业发展。

As one of the largest privately-owned partnerships, our 675 colleagues leverage the full ecosystem of Advent's global resources, including our Portfolio Support Group, insights provided by industry expert Operating Partners and Operations Advisors, as well as bespoke tools to support and guide our portfolio companies as they seek to achieve their strategic goals..

作为规模最大的私营合伙企业之一，我们的675位同事充分利用Advent全球资源的完整生态系统，包括我们的投资组合支持团队、由行业专家组成的运营合作伙伴和运营顾问提供的洞察，以及定制化工具，以支持和指导我们的投资组合公司实现其战略目标。

To learn more, visit our

欲了解更多信息，请访问我们的

website

网站

or connect with us on

或在以下平台关注我们

领英

。

*Assets under management (AUM) as of March 31, 2026. AUM includes assets attributable to Advent advisory clients as well as employee and third-party co-investment vehicles.

*截至2026年3月31日的管理资产规模（AUM）。管理资产规模包括归属于Advent咨询客户的资产，以及员工和第三方共同投资工具所持有的资产。

About NZCR Group

关于 NZCR 集团

NZCR Group, made up of NZCR, CMAX, Optimal, and Fusion, are a combined single clinical trials organisation offering integrated Phase I-IV clinical trial capability across New Zealand and Australia.

NZCR集团由NZCR、CMAX、Optimal和Fusion组成，是一家统一的临床试验机构，在新西兰和澳大利亚提供涵盖I至IV期的整合式临床试验服务。

With over 30 years' experience, the clinician led group has vast experience across a significant number of therapeutic areas and strong relationships with loyal sponsor companies in a multitude of international markets.

凭借三十余年的经验，这支由临床专家领导的团队在众多治疗领域拥有深厚的专业积累，并与众多国际市场上的忠实申办方企业建立了稳固的合作关系。

NZCR has some of the most experienced early and late phase research clinicians globally supported by a high-quality group of employees helping in the delivery of groundbreaking research to advance global health.

NZCR 拥有一些全球最具经验的早期和后期临床研究医生，并得到一支高素质员工团队的支持，共同推动突破性研究的实施，以促进全球健康事业的发展。

Media Contacts

媒体联系人

Canyon Partners:

峡谷合伙公司：

Kris Cole

克里斯·科尔

Prosek Partners

[email protected]

(310) 614 9208

Advent International:

安宏国际：